Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126396132 | 12639613 | 2 | F | 20160302 | 20160913 | 20160810 | 20160920 | EXP | GB-BAUSCH-BL-2016-018477 | BAUSCH AND LOMB | 71.00 | YR | F | Y | 57.00000 | KG | 20160920 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126396132 | 12639613 | 1 | PS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | Y | 40069 | 20 | MG | TABLET | |||||||
| 126396132 | 12639613 | 2 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | Y | 40069 | 20 | MG | TABLET | |||||||
| 126396132 | 12639613 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | Y | 40069 | 12 | MG | TABLET | |||||||
| 126396132 | 12639613 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | Y | 40069 | TABLET | /wk | ||||||||
| 126396132 | 12639613 | 5 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | Y | 0 | 1.3 | MG/M**2 | ||||||||
| 126396132 | 12639613 | 6 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | Y | 0 | 1.3 | MG/M**2 | ||||||||
| 126396132 | 12639613 | 7 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | Y | 0 | 1.3 | MG/M**2 | ||||||||
| 126396132 | 12639613 | 8 | C | ACYCLOVIR. | ACYCLOVIR | 1 | Oral | 0 | 800 | MG | BID | ||||||||
| 126396132 | 12639613 | 9 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 126396132 | 12639613 | 10 | C | ALLOPURINOL. | ALLOPURINOL | 1 | 0 | ||||||||||||
| 126396132 | 12639613 | 11 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 126396132 | 12639613 | 12 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 126396132 | 12639613 | 13 | C | CO-AMOXICLAV | AMOXICILLINCLAVULANIC ACID | 1 | Oral | 0 | 1875 | MG | TID | ||||||||
| 126396132 | 12639613 | 14 | C | DOXYCYCLINE. | DOXYCYCLINE | 1 | Oral | 0 | 100 | MG | QD | ||||||||
| 126396132 | 12639613 | 15 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 0 | 30 | MG | QD | ||||||||
| 126396132 | 12639613 | 16 | C | PAMIDRONATE | PAMIDRONATE DISODIUM | 1 | Intravenous (not otherwise specified) | 0 | 3 | MG | /month | ||||||||
| 126396132 | 12639613 | 17 | C | TINZAPARIN | TINZAPARIN | 1 | Oral | 0 | QD | ||||||||||
| 126396132 | 12639613 | 18 | C | TINZAPARIN | TINZAPARIN | 1 | Subcutaneous | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126396132 | 12639613 | 1 | Plasma cell myeloma |
| 126396132 | 12639613 | 5 | Plasma cell myeloma |
| 126396132 | 12639613 | 8 | Antiviral prophylaxis |
| 126396132 | 12639613 | 9 | Prophylaxis |
| 126396132 | 12639613 | 10 | Tumour lysis syndrome |
| 126396132 | 12639613 | 11 | Prophylaxis |
| 126396132 | 12639613 | 13 | Respiratory disorder |
| 126396132 | 12639613 | 14 | Respiratory disorder |
| 126396132 | 12639613 | 15 | Dyspepsia |
| 126396132 | 12639613 | 16 | Prophylaxis |
| 126396132 | 12639613 | 17 | Deep vein thrombosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126396132 | 12639613 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126396132 | 12639613 | Alopecia | |
| 126396132 | 12639613 | Blood glucose increased | |
| 126396132 | 12639613 | Blood phosphorus decreased | |
| 126396132 | 12639613 | Blood potassium decreased | |
| 126396132 | 12639613 | Confusional state | |
| 126396132 | 12639613 | Constipation | |
| 126396132 | 12639613 | Cough | |
| 126396132 | 12639613 | Depressed mood | |
| 126396132 | 12639613 | Diarrhoea | |
| 126396132 | 12639613 | Dizziness | |
| 126396132 | 12639613 | Dyspepsia | |
| 126396132 | 12639613 | Erythema | |
| 126396132 | 12639613 | Fatigue | |
| 126396132 | 12639613 | Headache | |
| 126396132 | 12639613 | Hypotension | |
| 126396132 | 12639613 | Injection site erythema | |
| 126396132 | 12639613 | Muscle spasms | |
| 126396132 | 12639613 | Myalgia | |
| 126396132 | 12639613 | Nausea | |
| 126396132 | 12639613 | Pyrexia | |
| 126396132 | 12639613 | Respiratory disorder | |
| 126396132 | 12639613 | Respiratory tract infection viral | |
| 126396132 | 12639613 | Synovial cyst | |
| 126396132 | 12639613 | Tearfulness | |
| 126396132 | 12639613 | Thirst | |
| 126396132 | 12639613 | Urinary tract infection | |
| 126396132 | 12639613 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126396132 | 12639613 | 1 | 20160229 | 20160320 | 0 | |
| 126396132 | 12639613 | 2 | 20160418 | 20160509 | 0 | |
| 126396132 | 12639613 | 3 | 20160416 | 20160601 | 0 | |
| 126396132 | 12639613 | 4 | 20160630 | 0 | ||
| 126396132 | 12639613 | 5 | 20160229 | 20160320 | 0 | |
| 126396132 | 12639613 | 6 | 20160418 | 20160509 | 0 | |
| 126396132 | 12639613 | 7 | 20160516 | 20160526 | 0 | |
| 126396132 | 12639613 | 8 | 20160229 | 0 | ||
| 126396132 | 12639613 | 9 | 20160229 | 0 | ||
| 126396132 | 12639613 | 11 | 2014 | 0 | ||
| 126396132 | 12639613 | 12 | 20160502 | 0 | ||
| 126396132 | 12639613 | 13 | 20160425 | 0 | ||
| 126396132 | 12639613 | 14 | 20160329 | 0 | ||
| 126396132 | 12639613 | 15 | 20160307 | 0 | ||
| 126396132 | 12639613 | 16 | 20131210 | 0 | ||
| 126396132 | 12639613 | 17 | 20160407 | 20160407 | 0 | |
| 126396132 | 12639613 | 18 | 20160519 | 20160519 | 0 |